PET scan to study an HIV-fighting antibody in the body
Part of Infections clinical trials.
This Phase 1/early study uses a special PET scan to see where an HIV-targeting antibody (VRC01) goes in the body. The study may help researchers understand how well this antibody reaches HIV-related targets, which could guide future HIV treatments or vaccines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You are either living with HIV or HIV-uninfected (both groups may be allowed)
- If you are living with HIV: you need recent viral load testing within the last 12 months
- If your viral load is suppressed (only in Phase 2): it must be below standard lab detection (example: <40 copies/mL)
- If you are living with HIV: your blood sample must suggest your virus could bind to VRC01
- You must be able to safely complete scans and blood tests (including blood count and kidney/liver limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
This Phase 2 study uses a special whole-body scan (PET-MR) to measure immune activity in people living with HIV. It may help researchers understand how well the immune system responds and how to better track HIV-related inflammation.
This Phase 2 study uses a special PET scan to look at how active your immune system is after a recent COVID-19 infection. The goal is to understand what the immune response looks like and whether this imaging approach could help guide care.
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
This study uses PET and MRI scans, plus blood tests and memory/thinking questionnaires, to understand what drives brain problems in people living with HIV even during treatment. It may help researchers learn why symptoms happen and how treatment relates to brain function.
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.